Fig. 3: Plasma ctDNA levels in the prospective cohort during the follow-up period relative to clinical progression.

Columns represent each patient’s age, gender, mutation status, scan modality used for monitoring, treatment and longitudinal quantitative ctDNA results. Columns are stratified into patients without or with disease progression, and the latter separated into those with detectable or undetectable ctDNA. b—Intracranial disease only. Grey*- Progressive disease. Red *- Presence of only intracranial malignant disease at progressive disease.